Takeda Pharmaceutical Company Ltd

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

Study of Motesanib (AMG 706) in Combination With Paclitaxel and Carboplatin for Advanced Non-Squamous Non-Small Cell Lung Cancer

Phase 3

Terminated

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Motesanib
Drug: Placebo
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2015-12-14

Last Posted Date: 2015-12-14

Lead Sponsor: Takeda

Target Recruit Count: 401

Registration Number: NCT02629848

A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease

Phase 3

Completed

Conditions: Colitis, Ulcerative
Crohn's Disease

Interventions: Drug: Vedolizumab SC

First Posted Date: 2015-12-02

Last Posted Date: 2024-07-10

Lead Sponsor: Takeda

Target Recruit Count: 746

Registration Number: NCT02620046

Locations: 🇧🇪
AZ Groeninge - Kennedylaan, Kortrijk, Belgium
🇺🇸
L & L Research Choices, Inc., Miami, Florida, United States
🇧🇷
Hospital Sao Vicente de Paulo, Passo Fundo, Rio Grande Do Sul, Brazil

and more 298 locations

A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old

Phase 2

Recruiting

Conditions: Gastroesophageal Reflux Disease (GERD)

Interventions: Drug: Dexlansoprazole

First Posted Date: 2015-11-26

Last Posted Date: 2024-11-13

Lead Sponsor: Takeda

Target Recruit Count: 70

Registration Number: NCT02616302

Locations: 🇲🇽
SMIQ S. de R.L. de C.V., Queretaro, Mexico
🇺🇸
Children's Center for Digestive Health Care, LLC, Atlanta, Georgia, United States
🇺🇸
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States

and more 24 locations

Efficacy of Naltrexone HCl/Bupropion HCl Extended Release Versus Placebo for Treatment of Weight Regain in Participants Post Bariatric Surgery

Phase 4

Withdrawn

Conditions: Weight Regain Post Bariatric Surgery

Interventions: Drug: Naltrexone HCl/Bupropion HCl
Drug: Naltrexone HCl/Bupropion HCl Placebo

First Posted Date: 2015-11-26

Last Posted Date: 2016-04-08

Lead Sponsor: Takeda

Registration Number: NCT02616315

A Study of Dexlansoprazole in Healing and Maintenance of Healed Erosive Esophagitis (EE) in Children

Phase 2

Recruiting

Conditions: Erosive Esophagitis

Interventions: Drug: Dexlansoprazole

First Posted Date: 2015-11-26

Last Posted Date: 2023-08-18

Lead Sponsor: Takeda

Target Recruit Count: 76

Registration Number: NCT02615184

Locations: 🇺🇸
Children's Center for Digestive Health Care, LLC, Atlanta, Georgia, United States
🇺🇸
D&H National Research Centers, Miami, Florida, United States
🇺🇸
Gastrointestinal Associates, PA, Flowood, Mississippi, United States

and more 24 locations

Evaluation of TAK-058 and Ondansetron on P50 Auditory Gating in Participants With Stable Schizophrenia

Phase 1

Terminated

Conditions: Schizophrenia

Interventions: Drug: TAK-058
Drug: Ondansetron
Drug: TAK-058 Placebo
Drug: Ondansetron Placebo

First Posted Date: 2015-11-25

Last Posted Date: 2017-05-01

Lead Sponsor: Takeda

Target Recruit Count: 11

Registration Number: NCT02614586

A Phase I/II Study for the Safety and Efficacy of Panitumumab in Combination With TAS-102 for Patients With Colorectal Cancer

Phase 1

Completed

Conditions: Colorectal Cancer

Interventions: Drug: Panitumumab + TAS-102

First Posted Date: 2015-11-24

Last Posted Date: 2019-07-31

Lead Sponsor: Takeda

Target Recruit Count: 56

Registration Number: NCT02613221

Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative Colitis

Phase 3

Completed

Conditions: Colitis, Ulcerative

Interventions: Drug: Vedolizumab 300 mg IV
Drug: Placebo IV
Drug: Placebo SC
Drug: Vedolizumab 108 mg SC

First Posted Date: 2015-11-23

Last Posted Date: 2022-05-25

Lead Sponsor: Takeda

Target Recruit Count: 383

Registration Number: NCT02611830

Locations: 🇺🇦
SI Divisional Clinical Hospital of Uzhgorod Station of ST&BA LZ Dep of Therapy SHEI Uzhgorod NU, Uzhgorod, Ukraine
🇺🇦
Private Small Enterprise Medical Center Pulse, Vinnytsia, Ukraine
🇩🇰
Odense Universitetshospital, Odense C, Denmark

and more 151 locations

Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease (CD)

Phase 3

Completed

Conditions: Crohn's Disease

Interventions: Drug: Vedolizumab SC 108 mg
Drug: Placebo
Drug: Vedolizumab IV 300 mg

First Posted Date: 2015-11-23

Last Posted Date: 2022-05-25

Lead Sponsor: Takeda

Target Recruit Count: 644

Registration Number: NCT02611817

Locations: 🇦🇺
Royal Melbourne Hospital, Melbourne, Victoria, Australia
🇧🇬
UMHAT 'Tsaritsa Yoanna - ISUL', EAD, Sofia, Bulgaria
🇭🇺
Semmelweis Egyetem, Budapest, Hungary

and more 191 locations

Phase 1 TAK-915 Single-Dose Positron Emission Tomography (PET) Occupancy Study

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: TAK-915

First Posted Date: 2015-10-22

Last Posted Date: 2016-07-21

Lead Sponsor: Takeda

Target Recruit Count: 12

Registration Number: NCT02584569

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy